ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
62,736.86
-0.24%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Terns Pharmaceuticals Inc (TERN)

  7. Terns Pharmaceuticals Inc (TERN) Noticias

TERN Terns Pharmaceuticals Inc

5.44
0.15 (2.84%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Terns Pharmaceuticals Inc TERN NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.15 2.84% 5.44 17:08:39
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
5.39 5.21 5.57 5.44 5.29
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
03/5/202415:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
29/4/202415:05GLOBETerns Pharmaceuticals Announces Data from Ongoing Phase 1..
10/4/202415:05GLOBETerns Pharmaceuticals Appoints Melita Sun Jung as Chief..
14/3/202415:05GLOBETerns Pharmaceuticals Reports Fourth Quarter and Full Year..
11/3/202415:05GLOBETerns Pharmaceuticals Announces Orphan Drug Designation..
07/3/202415:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
05/3/202417:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202415:05GLOBETerns Pharmaceuticals to Participate in Upcoming March..
15/2/202417:02EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/2/202407:57EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202415:20EDGAR2Form 8-K - Current report
07/2/202415:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New Chief..
07/2/202407:05GLOBETerns Pharmaceuticals Appoints Amy Burroughs as Chief..
02/2/202415:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
25/1/202418:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202415:05GLOBETerns Pharmaceuticals to Highlight 2024 Priorities and..
03/1/202415:05GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
29/11/202315:05GLOBETerns Pharmaceuticals to Present at the JMP Securities..
27/11/202315:05GLOBETerns Pharmaceuticals Mourns the Loss of Senthil Sundaram,..
14/11/202307:05GLOBETerns Pharmaceuticals Reports Third Quarter 2023 Financial..
13/11/202307:05GLOBETerns Pharmaceuticals Presents Late-Breaking Data from Phase..
09/11/202307:05GLOBETerns Pharmaceuticals to Participate in Upcoming November..
03/11/202315:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New..
02/11/202315:05GLOBETerns Pharmaceuticals Announces First Participant Dosed in..
19/10/202315:05GLOBETerns Pharmaceuticals to Participate in Upcoming Investor..
16/10/202307:05GLOBETerns Pharmaceuticals Announces Global Phase 1 Clinical..
10/10/202315:33EDGAR2Form 8-K - Current report
03/10/202315:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New..
06/9/202315:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New..
05/9/202315:05GLOBETerns Pharmaceuticals to Participate in Upcoming September..
08/8/202315:53EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202315:24EDGAR2Form 8-K - Current report
08/8/202315:15GLOBETerns Pharmaceuticals Reports Second Quarter 2023 Financial..
08/8/202315:05GLOBETerns Achieves Primary Endpoint and All Secondary Endpoints..
03/8/202317:00GLOBETerns Pharmaceuticals Reports Inducement Grant to New..
03/8/202316:22EDGAR2Form 8-K - Current report
03/8/202316:05GLOBETerns Pharmaceuticals Announces Leadership Transition
18/7/202315:05GLOBETerns Pharmaceuticals to Host Virtual Key Opinion Leader..
05/7/202315:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New..
26/6/202315:05GLOBETerns Pharmaceuticals Highlights New Preclinical Data for..
06/6/202315:30GLOBETerns Pharmaceuticals to Present at Goldman Sachs 44th..
02/6/202315:05GLOBETerns Pharmaceuticals Reports Inducement Grants to New..
25/5/202316:05GLOBETerns Pharmaceuticals Announces Publication of TERN-701..
24/5/202315:05GLOBETerns Pharmaceuticals to Present at Upcoming Investor..
22/5/202315:05GLOBETerns Pharmaceuticals to Highlight New Preclinical Data for..
15/5/202307:05GLOBETerns Pharmaceuticals Reports First Quarter 2023 Financial..
09/5/202315:05GLOBETerns Pharmaceuticals to Participate in the JMP Securities..

Su Consulta Reciente

NASDAQ
TERN
Terns Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados